Biotech Values

[DewDiligence]

PFE acquires private GT company* for $150M plus $495M in contingencies:

http://finance.yahoo.com/news/pfizer-aims-become-industry-leader-140000631.html

This acquisition significantly expands Pfizer’s expertise in gene therapy by providing Pfizer with a clinical and several pre-clinical assets that complement the company’s rare disease portfolio, an advanced recombinant Adeno-Associated Virus (rAAV) vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility that Bamboo acquired from the University of North Carolina earlier this year.

Just in time for PFE’s 2Q16 CC tomorrow.

*The 78% of Bamboo Therapeutics shares PFE did not already own.